US EditionVILAS Ventures Invests in $13.5M Series A3 Round for CND Life Sciences to Advance Neurodegenerative Diagnostics
Summary by Intelligence360 News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
VILAS Ventures Invests in $13.5M Series A3 Round for CND Life Sciences to Advance Neurodegenerative Diagnostics
BOCA RATON, Fla.–(BUSINESS WIRE)–VILAS Ventures, a healthcare-focused investment firm, announced its participation in the $13.5M Series A3 equity financing for CND Life Sciences, a pioneering diagnostics company developing innovative tools for the detection of neurodegenerative diseases. “Neurodegenerative diseases remain among the most urgent unmet needs in medicine,” said Daniel Livschutz, Managing Partner at VILAS Ventures. “CND’s Syn-One Te…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
